Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,370 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (387)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07147101 | Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment(HCC-IM-1) | recruiting | — | 150 | Fudan UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02174549 | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | recruiting | Phase 1 / Phase 2 | 25 | Teclison Ltd.INDUSTRY | 1 | Apr 20, 2026 |
| clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07538882 | AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma | recruiting | — | 108 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03259867 | Combination of TATE and PD-1 Inhibitor in Liver Cancer(TATE-PD1) | recruiting | Phase 2 | 54 | Teclison Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05623150 | CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome(CHALNA2) | recruiting | — | 710 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05842174 | Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma(TAQE) | recruiting | Phase 1 / Phase 2 | 93 | VA Office of Research and DevelopmentFED | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07476651 | Scout Dose of Resin Microspheres(LASER) | recruiting | N/A | 30 | Seoul National University HospitalOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07490262 | A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. | recruiting | Phase 2 / Phase 3 | 680 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05143619 | Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06485466 | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | recruiting | Phase 3 | 101 | Guohui XuOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05257590 | CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 95 | TaiRx, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06426992 | Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies | recruiting | N/A | 128 | Seoul National University HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07293468 | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)(BIIRTH) | recruiting | Phase 2 / Phase 3 | 106 | Tuen Mun HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05003895 | GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies | recruiting | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06910722 | Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy(RIS-TH) | recruiting | N/A | 36 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05733598 | Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | recruiting | Phase 2 | 60 | Replimune, Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06553885 | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | recruiting | Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07500220 | Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC(DUET-HCC) | recruiting | Phase 1 / Phase 2 | 30 | Beijing BiotechINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06687941 | A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors | recruiting | Phase 1 | 70 | Aptamer Sciences, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07331883 | Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2) | recruiting | Phase 2 | 35 | Ruijin HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495215 | A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection | recruiting | Phase 1 / Phase 2 | 20 | Yinghua XuOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07466602 | cfDNA Methylation for Liver Cancer Recurrence Detection | recruiting | — | 500 | Wuhan Ammunition Life-tech Co., LtdINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06140134 | Liver Transplantation in Intrahepatic Cholangiocarcinoma | recruiting | — | 30 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06345508 | Early Detection of Liver Cancer by QUS(QUS in HCC) | recruiting | — | 328 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05629845 | Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients(EUS-SPV) | recruiting | N/A | 84 | Chinese University of Hong KongOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07482059 | A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 33 | West China HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06077591 | Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors(PDO) | recruiting | N/A | 40 | Chinese University of Hong KongOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05528952 | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma(TERTIO) | recruiting | Phase 2 | 105 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07052253 | A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. | recruiting | Phase 2 | 100 | AkesoINDUSTRY | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05901519 | A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05095714 | FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.(FASTRAK) | recruiting | N/A | 944 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06537193 | Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment | recruiting | N/A | 455 | Asan Medical CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | recruiting | — | 500 | Mohamed Abdel-RahmanOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06859684 | Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)(HAIC-quad) | recruiting | Phase 2 | 25 | West China HospitalOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06530251 | A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) | recruiting | Phase 1 / Phase 2 | 280 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06885879 | Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma | recruiting | — | 15 | Chinese University of Hong KongOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06218420 | Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation(TRANSRAD-01) | recruiting | Phase 2 | 139 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06789848 | Ligufalimab and Cadonilimab in Advanced Liver Cancers | recruiting | Phase 2 | 64 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07432347 | Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches(DELIVER) | recruiting | — | 270 | Niguarda HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07436845 | Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy | recruiting | — | 90 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 21, 2026source: clinicaltrials